Do PD-1 and PD-L2 expressions have prognostic impact in hematologic malignancies?


Korkmaz S., Erdem S., Akay E., Tasdemir E. A. , Karaman H., Keklik M.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.1, pp.265-271, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 49 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.3906/sag-1706-194
  • Title of Journal : TURKISH JOURNAL OF MEDICAL SCIENCES
  • Page Numbers: pp.265-271
  • Keywords: PD-1, PD-L2, multiple myeloma, acute leukemia, chronic lymphocytic leukemia, MULTIPLE-MYELOMA, CLL PATIENTS, B7-H1 PD-L1, CELL, BLOCKADE, MOLECULES, LEUKEMIA, ANTIBODY, LIGANDS, PATHWAY

Abstract

Background/aim: PD-1 (programmed death-1) is an immune checkpoint receptor that modulates T-cell activity in peripheral tissues via interaction with its ligands, PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2). Tumor cells upregulate PD-L1 or PD-L2 to inhibit this T lymphocyte attack. Our goal was to determine the PD-1 and PD-L2 expression rates of various hematologic malignancies, and evaluate whether PD-1 and PD-L2 expressions have an impact on prognosis.